Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligands
- PMID: 20012148
- DOI: 10.1007/s00011-009-0143-2
Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligands
Abstract
Background: The human histamine H(4) receptor (hH(4)R) is a promising new target in the therapy of inflammatory or immune system diseases.
Methods: For the development of new hH(4)R ligands, a broad virtual screening was performed and two hits were identified. Their annelated heterocyclic core was optimized with regard to affinity and potency.
Results: Pharmacological characterization of the resulting diaminopyrimidines revealed different agonist and antagonist properties within the same scaffold.
Similar articles
-
2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.Bioorg Med Chem. 2009 Oct 15;17(20):7186-96. doi: 10.1016/j.bmc.2009.08.059. Epub 2009 Sep 2. Bioorg Med Chem. 2009. PMID: 19773175
-
2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.Bioorg Med Chem Lett. 2016 Jan 15;26(2):292-300. doi: 10.1016/j.bmcl.2015.12.035. Epub 2015 Dec 11. Bioorg Med Chem Lett. 2016. PMID: 26718844
-
Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands.Pharmazie. 2013 Jul;68(7):521-5. Pharmazie. 2013. PMID: 23923631
-
Major advances in the development of histamine H4 receptor ligands.Drug Discov Today. 2009 Aug;14(15-16):745-53. doi: 10.1016/j.drudis.2009.05.007. Epub 2009 May 27. Drug Discov Today. 2009. PMID: 19477292 Review.
-
Histamine H4 receptor ligands and their potential therapeutic applications.Expert Opin Ther Pat. 2009 Feb;19(2):119-35. doi: 10.1517/13543770802691085. Expert Opin Ther Pat. 2009. PMID: 19441913 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical